1. Effects of Intron 1 Sequences on Human PLP1 Expression: Implications for PLP1-Related Disorders
- Author
-
Patricia A. Wight
- Subjects
spastic paraplegia type 2 ,0301 basic medicine ,Review Article ,Disease ,Biology ,alternative splicing ,03 medical and health sciences ,0302 clinical medicine ,Pelizaeus–Merzbacher disease ,Gene expression ,Spastic ,medicine ,Animals ,Humans ,Gene ,Genetics ,General Neuroscience ,Alternative splicing ,Intron ,X-linked genetic disorders ,medicine.disease ,Introns ,Myelin proteolipid protein ,030104 developmental biology ,gene expression ,myelin proteolipid protein ,Neurology (clinical) ,Nervous System Diseases ,030217 neurology & neurosurgery - Abstract
Alterations in the myelin proteolipid protein gene ( PLP1) may result in rare X-linked disorders in humans such as Pelizaeus–Merzbacher disease and spastic paraplegia type 2. PLP1 expression must be tightly regulated since null mutations, as well as elevated PLP1 copy number, both lead to disease. Previous studies with Plp1-lacZ transgenic mice have demonstrated that mouse Plp1 ( mPlp1) intron 1 DNA (which accounts for slightly more than half of the gene) is required for the mPlp1 promoter to drive significant levels of reporter gene expression in brain. However not much is known about the mechanisms that control expression of the human PLP1 gene ( hPLP1). Therefore this review will focus on sequences in hPLP1 intron 1 DNA deemed important for hPLP1 gene activity as well as a couple of “human-specific” supplementary exons within the first intron which are utilized to generate novel splice variants, and the potential role that these sequences may play in PLP1-linked disorders.
- Published
- 2017